Furthermore, a reduced number of circulating CD38+/CD8+ T cells was observed in patients with highly advanced/metastatic SCCHN, CD38 being a both sensitive and specific marker for immune activation in various diseases. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.